Feed aggregator

Nanotech strategy shows promise for treating autoimmune disease

World Pharma News - Thu, 12/01/2022 - 11:00
Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases.

The scientists, who reported their results on November 23, 2022, in the journal ACS Nano, engineered cell-like "nanoparticles" that target only the immune cells driving an autoimmune reaction, leaving the rest of the immune system intact and healthy.

Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab

World Pharma News - Wed, 11/30/2022 - 11:00
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain,

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

World Pharma News - Tue, 11/29/2022 - 11:00
AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

The first potent COQ8 inhibitor targets ubiquinone biosynthesis

World Pharma News - Mon, 11/28/2022 - 13:00
Inhibition of the COQ8 protein could be beneficial in the treatment of diseases such as cancer. COQ8 is needed for the biosynthesis of coenzyme Q, also known as ubiquinone. A new collaborative study from the University of Eastern Finland, Washington University in St. Louis, University of Wisconsin-Madison, University of North Carolina at Chapel Hill and the Promega Corporation discloses the discovery and application of a new chemical probe to selectively inhibit human COQ8A in cells.

14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies

World Pharma News - Mon, 11/28/2022 - 11:00
8 - 9 February 2023, London, United Kingdom.
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.

AI tailors artificial DNA for future drug development

World Pharma News - Fri, 11/25/2022 - 13:00
With the help of an AI, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells' protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs than today.

Remdesivir reduces COVID-19 mortality in a real-world setting

World Pharma News - Fri, 11/25/2022 - 11:00
The COVID-19 pandemic has led to an explosion of clinical research resulting in the development of a variety of vaccines and treatments, although the efficacy of some remains controversial. Now, researchers from Japan report that remdesivir, a drug whose effectiveness has been debated, appears to make a big difference in Japanese patients with COVID-19 who received corticosteroids in the ICU.

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

World Pharma News - Thu, 11/24/2022 - 11:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)] against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

World Pharma News - Wed, 11/23/2022 - 11:00
Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now. Researchers of the University of Bristol-led study, published in Science Advances today, say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses - from the 2002 SARS-CoV outbreak to Omicron, the current variant of SARS-CoV-2, as well as dangerous variants that may emerge in future.

FDA Approves CSL-uniQure's Hemophilia B Gene Therapy, the Most Expensive Medicine in the World

Biospace news - Wed, 11/23/2022 - 02:00
The FDA approved CSL Behring and uniQure’s Hemgenix, a one-time gene therapy developed for adults with Hemophilia B,the companies announced Tuesday afternoon.

FDA Grants Priority Review to Takeda's Dengue Vaccine

Biospace news - Wed, 11/23/2022 - 02:00
The FDA granted priority review to Takeda’s Biologics License Application for TAK-003, a dengue vaccine candidate. The vaccine to date is only approved for use in Indonesia.

Arvinas’ Experimental Breast Cancer Drug Fails to Impress Analysts

Biospace news - Wed, 11/23/2022 - 02:00
Late Monday, Arvinas Inc. was forced to divulge the contents of its upcoming breast cancer data presentation, slated for the 2022 San Antonio Breast Cancer Symposium (“SABCS”).

Novartis and MMV Move to Pivotal Study with New Class of Drug for Malaria

Biospace news - Wed, 11/23/2022 - 02:00
Novartis and Medicines for Malaria Venture are moving into Phase III for a combination treatment targeting the rise of artemisinin-resistant Malaria infection.

Breaking the Silos: How One Doctor is Working to Reshape Medicine

Biospace news - Wed, 11/23/2022 - 02:00
BioSpace spoke with Dr. Kiana Aran to discuss her life, her accomplishments and what it means to be a successful woman in science on a global scale.

FDA approves first gene therapy to treat adults with Hemophilia B

World Pharma News - Tue, 11/22/2022 - 11:00
Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

GSK’s Blenrep Exits U.S. Market After Failing Confirmatory Trial

Biospace news - Tue, 11/22/2022 - 02:00
​​​​​​​Following a request from the FDA, GSK is withdrawing its multiple myeloma drug Blenrep from the U.S. market while continuing to push other combination trial programs.

Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic

Biospace news - Tue, 11/22/2022 - 02:00
The FDA granted argenx Priority Review status for the company’s BLA for SC efgartigimod for generalized myasthenia gravis.

Gratitude and Optimism: This Thanksgiving, BioSpace Celebrates Biopharma Wins

Biospace news - Tue, 11/22/2022 - 02:00
In a volatile year, marked with challenges, BioSpace is taking a pause to reflect on the many “wins” in biopharma.